Loading stock data…
$2.59-0.01 (-0.19%)
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies.
NeOnc Technologies Holdings, Inc. in the Healthcare sector is trading at $2.59 with a market capitalization of $80M. Wall Street consensus targets $17.00 (4 analysts), implying a +556.4% move over the next 12 months. The stock is currently near its 52-week low of $2.50, remaining 55.7% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.59M↓ | -$7.01M↑ | -$13.63M↓ | -$6.93M↓ | -$5.71M |
| Net Income | -$14.24M↓ | -$8.82M↑ | -$15.52M↓ | -$8.62M↓ | -$5.68M |
NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical ...